The Molecular Therapeutics of Cancer Program (MTCP) is a """"""""translational research"""""""" effort interfacing basic scientists with clinicians specializing in cancer diagnosis and treatment. The program has deep strengths in lung cancer research and has used this experience to catalyze additional research that links disease oriented teams and basic researchers. The MTCP also provides a major series of bridges through its interactions other Cancer Center Programs. The goals of the MTCP are to understand the molecular events (genetic and epigenetic) leading to cancer, as well as understanding the role of inter-individual genetic variation in developing and treating cancer, and use this information to provide a rationale basis for developing novel diagnostic, prevention, and therapeutic strategies. Specifically the MTCP seeks to: ? Understand the molecular pathogenesis of cancers with a focus on human tissues and model systems with a particular emphasis on lung cancer. This includes both description of the abnormalities and demonstrating their functional relevance as biologic, therapeutic and diagnostic targets. ? Develop new cancer imaging and nanotechnology tools to deliver novel imaging agents and therapeutics to highlight these targets in vivo in preclinical model and later in the clinic. ? Develop molecular therapeutics including those involving or combined with radiafion targeted at the abnormalities found in studies of the molecular pathogenesis as well as the identification and use of specific cell surface markers characteristic of certain cancers as therapeutic targets. ? Develop tumor molecular biomarkers that allow prediction of clinical behavior and response to specific treatments of individual patients so that treatment can be """"""""personalized."""""""" ? Use advances in the other Cancer Center Programs (Chemistry and Cancer, Cancer Cell Networks, and Development and Cancer) to inform each of these prior themes in a way that is unique to the Simmons Cancer Center and that will provide synergy of research efforts and facilitate translation to the clinic at UTSW.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA142543-04
Application #
8519959
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$45,298
Indirect Cost
$27,467
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Li, Xiangyi; Baek, GuemHee; Ramanand, Susmita G et al. (2018) BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. Cell Rep 22:796-808
Balasubramanian, Bijal A; Jetelina, Katelyn K; Bowen, Michael et al. (2018) Surveillance for colorectal cancer survivors in an integrated safety-net health system in the United States. Int J Care Coord 21:26-35
Li, Ran; Chiguru, Srinivas; Li, Li et al. (2018) Targeting Phosphatidylserine with Calcium-Dependent Protein-Drug Conjugates for the Treatment of Cancer. Mol Cancer Ther 17:169-182
Wijayatunge, Ranjula; Holmstrom, Sam R; Foley, Samantha B et al. (2018) Deficiency of the Endocytic Protein Hip1 Leads to Decreased Gdpd3 Expression, Low Phosphocholine, and Kypholordosis. Mol Cell Biol 38:
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Miyata, Naoteru; Morris, Lindsey L; Chen, Qing et al. (2018) Microbial Sensing by Intestinal Myeloid Cells Controls Carcinogenesis and Epithelial Differentiation. Cell Rep 24:2342-2355
Hamann, Heidi A; Shen, Megan J; Thomas, Anna J et al. (2018) Development and Preliminary Psychometric Evaluation of a Patient-Reported Outcome Measure for Lung Cancer Stigma: The Lung Cancer Stigma Inventory (LCSI). Stigma Health 3:195-203
Murphy, Caitlin C; Singal, Amit G; Baron, John A et al. (2018) Decrease in Incidence of Young-Onset Colorectal Cancer Before Recent Increase. Gastroenterology 155:1716-1719.e4
Mokdad, Ali A; Xie, Xian-Jin; Zhu, Hong et al. (2018) Statistical justification of expansion cohorts in phase 1 cancer trials. Cancer 124:3339-3345
Murphy, Caitlin C; Fullington, Hannah M; Alvarez, Carlos A et al. (2018) Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer 124:2850-2857

Showing the most recent 10 out of 501 publications